Novartis India Limited

NOVARTIND

INE234A01025

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:13:49 2025-06-20 am EDT			5-day change	1st Jan Change
1,014.85 ^INR	+1.59%		+2.41%	+10.33%

May. 09	Novartis India Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025	CI
Apr. 01	Market Volatility Derails Novartis' Plan to Sell Stake in its India Arm	CI

Novartis India Limited Reports Earnings Results for the First Quarter Ended June 30, 2024

Published on 07/29/2024 at 04:01

Novartis India Limited reported earnings results for the first quarter ended June 30, 2024. For the first quarter, the company reported sales was INR 922.9 million compared to INR 906 million a year ago. Revenue was INR 1,027 million compared to INR 1,030.7 million a year ago.

Net income was INR 257.4 million compared to INR 202.6 million a year ago. Basic earnings per share from continuing operations was INR 10.42 compared to INR 8.21 a year ago.

Latest news about Novartis India Limited

Novartis India Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025	May. 09	CI
Market Volatility Derails Novartis' Plan to Sell Stake in its India Arm	Apr. 01	CI
Novartis India's Net Profit Declines in Fiscal Q3	Jan. 28	MT
Novartis India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024	Jan. 28	CI
Novartis India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024	24-10-25	CI
PE Firms Reportedly Queue Up for Novartis' Indian Arm	24-10-12	CI
Alkem Labs Reportedly in Talks to Acquire Novartis India from Its Swiss Parent	24-09-26	CI
Novartis India Clarifies on Reports Indicating Alkem's Interest in It	24-09-26	CI
Novartis India Limited Reports Earnings Results for the First Quarter Ended June 30, 2024	24-07-29	CI
Novartis India Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	24-05-10	CI
Novartis India Limited Announces Appointment of Chandni Maru as Company Secretary and Compliance Officer	24-05-08	CI
Novartis India Limited Announces Resignation of Nikhil Malpani as Company Secretary and Compliance Officer, Effective from April 30, 2024	24-04-01	CI
Novartis Eyes Sale of Listed Unit in India	24-03-22	CI
Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB...	24-02-19
Swiss Market Index Closes in the Green on Healthcare Stocks Boost	24-02-19	MT
Novartis Launches Strategic Review of Listed Indian Business	24-02-19	MT
Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India	24-02-19	CI
Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm	24-02-17	CI
Dr Reddy'S In Race To Acquire Novartis AG's Stake In Novartis India - CNBC TV-18	24-02-17	RE
Novartis India Limited Announces Completion of Tenure of Jai Hiremath as Independent Director, Effective March 31, 2024	24-02-17	CI
Novartis AG Announces A Strategic Review of India Unit	24-02-16	CI
Novartis India Limited Announces Resignation of Mr. Sanjay Murdeshwar as Managing Director, Effective April 02, 2024	24-01-25	CI
Novartis India Limited Announces Resignation of Mr. Sanjay Murdeshwar as Vice-Chairman, Effective April 02, 2024	24-01-25	CI
Novartis India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	24-01-25	CI
Novartis India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	23-10-26	CI

Chart Novartis India Limited

Duration

Period

NOVARTIND: Dynamic Chart

Company Profile

Novartis India Limited is an India-based company. The Company is engaged in the business of trading pharmaceuticals. The Companyâs brands hold key positions in therapeutic areas, such as, in the bone and pain therapeutic area. Its brand is Voveran. In the transplantation immunology therapeutic area, the Company's brands include Simulect, Certican, Sandimmun, Neoral and Myfortic. In the neurosciences therapeutic area, its brands include Tegrital and Exelon.

Employees

Sector

Pharmaceuticals

Calendar

Jul. 22 - Détachement de for final dividend

More about the company